恶性肿瘤患者幽门螺杆菌抗体的检测  

Detection of Anti-HP Antibodies in Serum of Patients with Malignant Tumors

作　　者：雷秀霞[1] 陈小辉[1] 梁颜笑[1] 

机构地区：[1]广东省广州市第一人民医院检验科,广州510180

出　　处：《热带医学杂志》2005年第4期481-483,共3页Journal of Tropical Medicine

摘　　要：目的观察各种恶性肿瘤病患者幽门螺杆菌感染情况,了解恶性肿瘤的发生、发展与幽门螺杆菌感染的相关关系。方法将确诊的150例恶性肿瘤患者,41例慢性肝炎患者和103例普通体检者血清采用金标免疫斑点法作幽门螺杆菌抗体HP-Ab测定。60例肝癌、胃癌患者,41例慢性肝炎患者和103例普通体检者血清采用EIA法作CagA-HP-IgG抗体(产细胞毒素幽门螺杆菌抗体)测定。结果恶性肿瘤组幽门螺杆菌的感染率为80.0%,显著高于慢性肝炎组的53.6%和正常对照组50.5%,经Ridit分析,U值分别等于5.518和5.924,P<0.01。肝癌、胃癌患者CagA+-HP-IgG检出率分别为45.5%和62.5%,显著高于慢性肝炎组和正常对照组的29.3%和27.2%,P<0.05。结论幽门螺杆菌感染易诱发恶性肿瘤。Objective To observe Helicobacter pylori (HP) infection in patients with malignant tumors and study on the relationship between HP infection and the development of the malignant tumors. Method Serum anti-HP antibodies were measured in 150 patients with malignant tumors,41 patients with chronic hepatitis and 103 healthy people. CagA-HP-IgG detection was also performed in 60 cases of liver and gastric cancer, 41 cases of patients with chronic hepatitis and 103 healthy people. Results The rates of HP infection in the malignant tumors patients, hepatitis patients and control group were 80.0%, 53.6% and 50.5%, respectively (P><0.01). The positive rates of CagA-HP-IgG detection in liver and gastric cancer patients, hepatitis patients and control groups were 45.5% , 62.5% , 29.3% and 27.2%, respectively,(P<0.05). Conclusion HP infection may easily lead to the malignant tumors.

关 键 词：恶性肿瘤 幽门螺杆菌抗体 酶免疫分析 

分 类 号：R378[医药卫生—病原生物学]